While one in eight women in the U.S. will develop breast cancer in their lifetime, the good news is that the cancer has an 89% five-year survival outlook. CRI is proud to have Sarah Sammons, MD, the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute, further discuss this important type of cancer. Dr. Sammons seeks to improve outcomes for breast cancer patients, particularly for those experiencing the complications of breast cancer metastasis.
Immune to Cancer: The CRI Blog
Patient Immunotherapy Summit: Breast Cancer Brief
For media inquiries, please contact us at [email protected]
Stay up to date
Join our email list for updates on cancer immunotherapy research, events, and opportunities to get involved with the Cancer Research Institute. Sign up below and be a force for change in the fight against cancer.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.
